From CBD to THCV: Clinical Trials & ECS Brands

ECS Brands has received support from the NIH and guidance from the Mayo Clinic to assess THCV in clinical trials. In this article, Aaron Green interviews Arthur Jaffee, Founder & CEO of ECS Brands to learn more about their recent clinical safety trial involving cannabinoids.

The post From CBD to THCV: Clinical Trials & ECS Brands appeared first on Cannabis Industry Journal.

How Rare Cannabinoids Will Impact Investing

There has been an explosion of interest in THCV recently, as well as a number of other uncommon cannabinoids. There will be big winners and losers in rare cannabinoid markets, but at the end of the day, the highest quality and lowest cost producers will capture most of these markets.

The post How Rare Cannabinoids Will Impact Investing appeared first on Cannabis Industry Journal.